BDL
VRTX icon

Banque de Luxembourg’s Vertex Pharmaceuticals VRTX Stock Holding History

Banque de Luxembourg’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40
Closed -$19.4K – 92
2025
Q2 		$19.4K Hold
40
– – 0.01% 83
2025
Q1 		$19.4K Buy
+40
New +$18.6K 0.01% 83

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Banque de Luxembourg's VRTX Position: Q3 2025 in Review

Banque de Luxembourg sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 40 shares — an estimated $19.4K sold.

Banque de Luxembourg first reported a position in VRTX in Q1 2025 and held it in 2 quarters. The position peaked at $19.4K in Q2 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Banque de Luxembourg reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Banque de Luxembourg sold 40 Vertex Pharmaceuticals shares in Q3 2025, an estimated $19.4K.
  • Banque de Luxembourg first reported a position in Vertex Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Banque de Luxembourg's Vertex Pharmaceuticals position peaked at $19.4K in Q2 2025.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Banque de Luxembourg's 13F filing for Q3 2025, filed 17 Oct 2025.